expressing tumors. In vitro, HT1080/DR4 cells were 270-fold, 6.4-fold and 2.8-fold more resistant than parental cells to doxorubicin, PC and DC, respectively. Pyridine analogue PAK-104P completely restored drug sensitivity to PC and DC, while no effect of PAK-104P on parental HT1080 cells was observed.
Conclusions: Both taxoids, when given at their MTDs, showed significant efficacy against parental HT1080 tumor xenografts. However, docetaxel at its MTD was significantly more active against MRP-expressing tumor xenografts than paclitaxel. Furthermore, in vitro resistance of HT1080/DR4 cells was higher for PC (6.4-fold) than for DC (2.8-fold). Since PAK-104P completely restored sensitivity to both taxoids, the observed resistance appears to be related to MRP. These data suggest, that docetaxel is not as readily transported by MRP as paclitaxel leading to an increased therapeutic ratio in MRPexpressing tumors in vivo. Therefore, docetaxel may have therapeutic advantages in the clinical treatment of MRPexpressing tumors.
Introduction
Paclitaxel (Taxol) and docetaxel (Taxotere) are the first of a new class of clinically potent and promising microtubule-targeting agents for the treatment of cancer [1, 2] . Both taxoids are semisynthetic derivatives from 10-deacetyl baccatin III, an inactive precursor extracted from the needles of Taxus baccata, the European yew tree. The cellular mechanisms of cytotoxic action of paclitaxel and docetaxel involve specific covalent binding to assembled tubulin, resulting in promotion and stabilization of persistent interphase microtubule complexes [3, 4] . Recent studies provided evidence that docetaxel is more potent in promoting tubulin polymerization and inhibiting cell replication than paclitaxel in vitro [5] [6] [7] and in vivo [8] .
Cellular resistance to taxoids has been mainly associated with the occurrence of abnormal tubulin subunits [9, 10] or with expression of the mdrl gene-encoded membrane-glycoprotein P-170 [11] [12] [13] , resulting in altered cellular drug accumulation of both taxoids. However, there is evidence that resistance to paclitaxel may not result in complete cross-resistance to docetaxel [14, 15] .
Recently, MDR has also been associated with expression of a Mr 190,000 membrane phosphoglycoprotein [16] [17] [18] [19] , designated MRP [16] . MRP belongs to the ATPbinding cassette transmembrane transporter superfamily and has been related to the multispecific organic anion transporter (MOAT) [20] . Recent in vitro and in vivo studies provided evidence that MRP function considerably differs from that of Pgpl70-associated MDR in terms of substrate specificity [17, 21] , lack of reversal of MRP-mediated resistance by classical MDR modulators (e.g., verapamil [22, 23] , PSC-833 [23, 24] ) and involvement of the GSH pathway in MRP function [20, [25] [26] [27] [28] . In contrast to the Pgpl70 phenotype, expression of MRP only confers a low degree of resistance to paclitaxel in vitro [21, 24, 29] . The antitumor activity of docetaxel in MRP-mediated MDR has not been elucidated so far.
Both taxoids are clinically effective against a variety of solid tumors, especially ovarian cancer [30] [31] [32] , breast cancer [33] [34] [35] and non-small-cell lung cancer [36, 37] . However, the results of clinical studies may suggest that docetaxel is more active when compared with paclitaxel against some solid tumors, especially breast cancer [35, 38] and non-small-cell lung cancer [37] . Molecular and immunohistochemical studies on human tumor samples showed, that breast cancer [39, 40] and nonsmall-cell lung cancer cells significantly express MRP mRNA and protein [41, 42] . Thus, the role of MRP as predictor for clinical response to taxoids might be of significant interest.
We have recently established in athymic nude mice (nu/nu) parental human fibrosarcoma HT1080 xenografts (MRP-/Pgpl70-negative) and multidrug resistant MRP-expressing HT1080/DR4 xenografts (MRP-positive, Pgpl70-negative), which are highly resistant to doxorubicin [24, 27] and partially resistant to paclitaxel [24] . In the present study, we compared the therapeutic efficacy of docetaxel versus paclitaxel against doxorubicin-resistant human tumor xenografts that overexpress the MRP but not the Pgpl70.
Materials and methods

Cell lines
The characteristics of the human fibrosarcoma cell line HT1080 (parental) and the doxorubicin-selected MDR subline HT1080/DR4 (MRP and LRP positive, Pgpl70 negative) have been described previously by M.L. Slovak (Department of Cytogenetics, City of Hope National Medical Center, Duarte, CA) [18, 43] . HT1080/DR4 cells were found to be highly resistant to doxorubicin, etoposide, vincnstine [44] , but not to cisplatin and melphalan (28) . HT1080 and HT1080/ DR4 cells were grown as monolayers in Eagle's minimum essential medium supplemented with Earle's BSS and 10% heat inactivated fetal calf serum (FCS), non-essential amino acids and L-glutamine.
Cell cultures were kept under exponential growth conditions in a humidified atmosphere of 5% CO 2 in air at 37 °C.
Cytotoxlcity evaluation in vitro
In vitro drug sensitivity of the HT1080 cell lines was assessed by the sulphorhodamine B assay as described earlier [45] . In brief, cells in exponential growth were seeded at a density of 1000 cells/well in 96-well microtitre plates (Falcon, Becton Dickinson Labware, Plymouth, UK) and allowed to attach overnight. Twenty-four hours later the monolayers were exposed to doxorubicin (two hours), paclitaxel (three hours) or docetaxel (three hours) in the presence or absence of the modulator PAK-104P [46] , Following drug exposure, cells were washed, then incubated in drug-free medium in the continuous presence or absence of the modulator. Previous studies demonstrated that the highest reversal of drug resistance was achieved with a continuous exposure to the modulator (data not shown). At four cell doubling times after drug treatment, cells were fixed with trichloroacetic acid, washed and stained with sulphorhodamine B as orgmally described [45] . Absorbance was measured at 570 nm using a 96-well plate reader (340 EL BIO Kinetics Reader, BIO-TEK Instruments Inc., Winooski, VT). The drug concentration which inhibited the cell growth by 50% (IC50) was determined from semiloganthmic dose-response plots.
Mice
Eight-to 12-week-old female athymic nude mice (nu/nu) (body weight 20-25 g) were obtained from Harlan Sprague-Dawley, Inc., Indianapolis, IN. They were kept five/cage under specific-pathogen-free conditions with water and food ad libitum.
Tumor xenografts
The growth of HT1080 and HT1080/DR4 cells in athymic nude mice was established as previously described [24, 27] . In brief, tumor xenografts of human fibrosarcoma HT1080 and HT1080/DR4 cells were established by implanting 10 6 and 10 7 cells s.c, respectively. Tumor xenografts were maintained for several generations by subcutaneous transplantation of non-necrotic tumor tissue of approximately 50 mg (via trocar). Drug treatments were initiated when the tumor sizes reached 150-200 mg.
MRP expression: RT-PCR amplification and Northern blot hybridization
One ng total RNA of HT1080/DR4 cells was used for MRP cDNA probe synthesis with an RNA PCR kit (Perkin-Elmer, Branchburg, NJ). Reverse transcription was performed using random hexamers as primer according to the instructions of the manufacturer. The PCR reaction was carried out in a GeneAmp 2400 PCR system (Perkin-Elmer) for 30 cycles of denaturation (95 °C, 60 sec), annealing (60 °C, 60 sec) and extension (72 °C, 90 sec). The MRP-specific PCR primers (position 2540-2865, [16] ) were as follows: sense 5'-CGTGTACTCCAACGCTGAC-3' and antisense 5'-CTGGACC-GCTGACGCCCGTGAC-3', respectively. The PCR products were gel purified and the band of the expected size of 326 bp was isolated.
Northern blot analysis of MRP mRNA expression was performed as described earlier [28] . In brief, total RNA was isolated from fresh tumor samples (approximately 100 mg) of HT1080 and HT1080/DR4 xenografts by a single-step guanidine isothiocyanate-phenol-chloroform extraction [47] . Blots containing 20 ug of total RNA were prehybridized at 65 °C (one hour) in 0.5 M dipotassium hydrogen phosphate buffer containing 7% (w/v) SDS, 1% (w/v) BSA, and 1 mm EDTA. The hybridization was performed overnight at 65 °C with a random-primed, [alpha-
32 P]dCTP-labeled MRP cDNA fragment corresponding to nucleotides 2540 to 2865 of MRP cDNA [16] . After autoradiography, blots were stripped and reprobed with a [
32 P]-labeled cDNA probe for G3PDH (Clontech Laboratories Inc., Palo Alto, CA) to determine variation in RNA loading.
Drug treatment
Doxorubicin (Farmitalia Carla Erba S.P.A., Milan, Italy) was dissolved in sterile 0.9% saline and injected i.v. push at the maximum tolerated dose of 10 mg/kg. Docetaxel (Taxotere, RP 56976, NSC 628503), a gift from Rhone-Poulenc Rorer (Vitry-sur-Seine, FranceX was first formulated in ethanol/polysorbate 80 (1/1, v/v), then 5% glucose (w/v) in water was added (1:10) (stock solution 1 mg/ml). Paclitaxel (Taxol, NSC 125973) was provided by Bristol-Myers Squibb (Princeton, NJ) and dissolved in Dilut 12 (polyethoxylated castor oil containing 50% absolute ethanol [kindly provided by the National Cancer Institute, Bethesda, MD]) at a concentration of 6 mg/ml. Treatment of nude mice with the vehicle controls alone showed no antitumor activity at the concentrations used (data not shown). Docetaxel and paclitaxel were administered i.v. as a three-hour infusion at the MTD with 40 mg/kg and 50 mg/kg, respectively. All solutions were prepared fresh and used immediately. The MTD was defined as the maximum dose that could be administered to tumor bearing mice without causing drug-related lethality and a body weight loss more than 15%. Fifteen to 20 nude mice per group were treated in at least three independent experiments. The present study was performed in accordance with Institutional Animal Care and Use Committee guidelines.
Tumor measurements and body weight
The tumor weight (mg) was determined by measurements of the longest axis (L) and shortest axis (W) of each tumor with a Vernier caliper and calculated assuming unit density by the following formula: 1 /2 (L x W 2 ). Relative tumor volume (RTV) was calculated using the formula RTV (%) = V^/V, x 100, where V* represents the tumor volume on day x and V; the initial tumor volume. As a general policy, mice were sacrificed when the tumor sizes exceeded 2.0 g. To evaluate drug toxicity, body weights of mice were recorded at the time of tumor measurements.
Antitumor activity
Antitumor activity was assessed by maximum inhibitory rate (MIR) of the RTV of the treated over the untreated mice. The tumor doubling time (TD) was defined as the mean time for the tumor to reach twice the initial size. PR was defined as a reduction in tumor size greater than 50% and CR as the inability to detect a tumor by palpation at the initial site of the tumor appearance for more than 60 days post treatment (cures).
Statistical analysis
The differences between the mean values were analysed for significance using the unpaired two-tailed Student's (-test for independent samples; /"-values < 0.05 were considered to be statistically significant.
Results
Modulation of in vitro drug sensitivity
Cultured parental HT1080 and MRP-expressing HT1080/DR4 cells were exposed to doxorubicin, paclitaxel and docetaxel and the results are shown in Table 1 . While HT1080/DR4 cells were 270-fold resistant to doxorubicin, only 6.4-fold and 2.8-fold drug resistance to paclitaxel and docetaxel was observed, respectively. These data indicate that docetaxel was about 100-fold and 2.5-fold more active against MRP-expressing tumor cells than doxorubicin and paclitaxel, respectively. Cellular exposure to noncytotoxic concentrations of PAK-104P, a potent modulator of MDR1 and MRPmediated multidrug resistance [46] , completely reversed in HT1080/DR4 cells resistance to docetaxel and paclitaxel (remaining resistance factor for 5.0 uM PAK-104P 1.1 and 1.3 with P >0.05, respectively), while no significant effect was observed on parental HT1080 cells (Table 1) .
Northern blot analysis of MRP mRNA expression in vivo
Expression of MRP in multidrug resistant HT1080/ DR4 tumor xenografts during repeated tumor passages was confirmed by Northern blot analysis and the results are shown in Figure 1 (upper panel). Applying an MRPspecific 326 bp [ 32 P]CTP-labeled cDNA probe, significant staining for MRP mRNA was observed in tumor samples of HT1080/DR4 xenografts, whereas no signal was detectable for parental HT1080 tumors. No differences in RNA loading were observed using a cDNA probe for G3PDH (Figure 1, lower panel) . The observed significant MRP mRNA expression in HT1080/DR4 xenografts is consistent with our previously reported immunohistochemical analysis of cellular MRP protein expression and distribution in HT1080/DR4 tumors in vivo [27] , applying the monoclonal antibody MRPm6 on paraffin sections. In addition, parental HT1080 and resistant HT1080/DR4 tumors were negative for Pgpl70 expression as shown by immunohistological analysis and RT-PCR (data not shown).
Antitumor activity in mice bearing xenografts
For the present study, the MTDs of single doses of doxorubicin, paclitaxel and docetaxel were determined as follows: doxorubicin, 10 mg/kg (i.v. push); paclitaxel, 50 mg/kg (three-hour i.v. infusion); and docetaxel 40 mg/kg (three-hour i.v. infusion). The MIR, TD, and MWL were compared for untreated and all drug-treated groups as shown in Table 2 and Figure 2 . The data demonstrate the therapeutic efficacy of paclitaxel and docetaxel against parental HT1080 tumors and the superiority of both taxoids over doxorubicin in terms of tumor response. However, when the therapeutic efficacy of docetaxel and paclitaxel treatment were compared against parental HT1080 xenografts, docetaxel was 1.5-fold more active than paclitaxel in terms of complete tumor regression (CR rates for docetaxel and pachtaxel were 60% and 40%, respectively). In contrast, doxorubicin at its MTD induced no tumor regression in nude mice bearing MRP-expressing HT1080/DR4 tumors (CR and PR rate 0%, respectively) ( Table 2 ). Using the MTD of paclitaxel and docetaxel (three-hour i.v. infusion), MRP-expressing HT1080/DR4 tumors were partially cross-resistant to paclitaxel (CR and PR rate 0% and 10%, respectively), while docetaxel treatment resulted in a significant tumor response (overall response rate 100% with 60% cures). Furthermore, kinetic of docetaxel-induced regression of HT1080/DR4 tumors was not different when compared for parental HT1080 xenografts with maximal induction of complete tumor response at day 16 after therapy ( Figure 3 ).
Discussion
Although docetaxel and paclitaxel have significant clinical efficacy against a variety of solid tumors (e.g., breast cancer [33] [34] [35] , non-small-cell lung cancer [NSCLC] [36, 37] ), the inherent presence or emergence of drug-resistant tumor clones presents a major obstacle to achieve long time survival for patients with advanced disease. Therefore, the detection of mechanisms leading to intrinsic or acquired drug resistance may play an important role to identify a more effective therapy for those patients.
We have recently established the MRP-expressing human fibrosarcoma xenograft HT1080/DR4 and documented in vivo resistance to doxorubicin [24, 27] . The present study compared the therapeutic index of paclitaxel and docetaxel in athymic nude mice bearing parental HT1080 and multidrug resistant MRP-expressing HT1080/DR4 tumor xenografts.
The single doses of 40 mg/kg docetaxel and 50 mg/ kg paclitaxel given as three-hour i.v. infusion appear to be maximal, because the total body weight loss was little less than 15% (Table 2), the limit set for reversible toxicity. Using the same treatment schedule, higher doses of paclitaxel and docetaxel produced significant toxicities and resulted in treatment-related deaths (data not shown).
The data reported herein demonstrated that: a) treatment of nude mice with the maximum tolerated doses of paclitaxel (50 mg/kg; three-hour i.v. infuison) and docetaxel (40 mg/kg; three-hour i.v. infusion) produced complete regression of parental HT1080 tumors in 40% and 60%, respectively; b) docetaxel given at an equitoxic dose was about 1.5-fold more efficient against parental HT1080 xenografts than paclitaxel in terms of complete tumor regression ( Figure 3 and Table 2 ), results which are consistent with reported data on nude mice bearing advanced B16 melanoma tumor xenografts [8] . However, Nicoletti et al. recently reported no differences in terms of antitumor efficacy between docetaxel and paclitaxel treatment against human ovarian carcinoma xenografts (48); c) highly doxorubicin-resistant MRPexpressing HT1080/DR4 tumors were partially crossresistant to paclitaxel (CR and PR rate 0% and 10%, respectively), while treatment of nude mice with docetaxel at its MTD significantly induced tumor regression of HT1080/DR4 tumors (CR and PR rate 60% and 40%, respectively) ( Figure 3 , Table 2 ). These results document the superiority of docetaxel over paclitaxel in terms of tumor response and the lack of cross-resistance between doxorubicin and docetaxel in MRP-mediated MDR in vivo.
Cellular mechanisms of resistance to taxoids have been associated with overexpression of the MDR] gene product Pgpl70, resulting in altered cellular drug accumulation and retention [11] [12] [13] . However, Pgpl70-expressing cell lines may display incomplete cross-resistance to docetaxel (e.g., P388/Dox cells [14] ). Reversal of Pgpl70-mediated resistance to taxoids by cyclosporine derivative PSC-833 and other chemosensitizers (e.g., verapamil) have been reported [49] [50] [51] and the results of a phase I cross-over study of paclitaxel ± r-verapamil in patients with advanced breast cancer demonstrated that the combination of 225 mg/m 2 r-verapamil orally every four hours can be given safely with paclitaxel 200 mg/m 2 by 3-hour i.v. infusion [52] .
In MRP-expressing HT1080/DR4 tumor cells, a low degree of resistance to paclitaxel (6.4-fold) and docetaxel (2.8-fold) was observed (Table 1) , results which are consistent with previously reported data on drugselected cell lines [24, 29] . Pyridine analogue PAK-104P [46] , a potent modulator of MRP-mediated MDR [24, 53] , completely restored drug response to paclitaxel and docetaxel in vitro (Table 1 ) and in vivo (paclitaxel [24] ). Furthermore, PAK-104P inhibited the MRPmediated drug efflux of doxorubicin and rhodamine in MRP-expressing HT1080/DR4 and HL60/ADR cells, resulting in significant reversal of resistance to doxorubicin [24, 54] . Only recently, it has been shown that PAK-104P competitively inhibits the ATP-dependent [ 3 H]leukotrieneC 4 transport of membrane vesicles of MRP-expressing CA120 cells [53] . Thus, in vitro reversal of cellular resistance to both taxoids by the pyridine analogue PAK-104P in HT1080/DR4 cells is likely related to inhibition of MRP-mediated drug efflux.
Cultured MRP-expressing HT1080/DR4 cells were only 6.4-fold resistant to paclitaxel in vitro, however, treatment of nude mice with paclitaxel at its MTD produced no significant growth inhibition of MRP-expressing HT1080/DR4 tumors (CR and PR rate 0% and 10%, respectively), demonstrating at least partial resistance to paclitaxel in tumors with high expression of MRP. Interestingly, we have previously shown that PAK-104P at a non-toxic dose (100 mg/kg i.v. x4) completely restored tumor response to paclitaxel in nude mice bearing HT1080/DR4 tumors (CR and PR rate 40% and 40%, respectively) with no increase in treatmentrelated toxicity [24] . Treatment of mice with docetaxel at its MTD resulted in 60% complete tumor regression (cures) ( Table 2 and Figure 3) , demonstrating the lack of cross-resistance between docetaxel and doxorubicin in MRP-mediated MDR in vivo.
The importance of MRP in clinical drug resistance has not been fully established, however, overexpression of MRP mRNA and protein have been reported in human tumor samples (e.g., breast cancer [39, 40] , NSCLC [42] ). Nooter et al. reported that MRP expression might be of prognostic significance in subgroups of patients with breast cancer [55] . Chuman et al. [41] suggested that expression of MRP is responsible, at least in part, for drug resistance in squamous-cell carcinomas of the lung. Of importance is that NSCLC cells express only low levels of MDR1 mRNA/protein [56] and only approximately 40% of patients with advanced breast cancer are positive for MDRl/Pgpl70 [57] . Furthermore, an ongoing phase II trial of docetaxel in patients with paclitaxel-resistant breast cancer, demonstrated response to docetaxel [38] . Based on these results, it appears that expression of MRP may be an important predictor for drug response to taxoids in vivo.
In conclusion, a comparative study of the therapeutic efficacy of docetaxel and paclitaxel was conducted in nude mice bearing parental HT1080 and doxorubicinresistant HT1080/DR4 tumors that express MRP. Our results demonstrate that high levels of expression of MRP mRNA and MRP protein may confer resistance to paclitaxel but not to docetaxel in vivo. In contrast, docetaxel at equitoxic doses produced significant growth inhibition of MRP-expressing tumor xenografts, resulting in potentiation of the therapeutic index and displaying the lack of cross-resistance to doxorubicin in MRPmediated MDR. These preclinical data demonstrate that the MRP-mediated low in vitro resistance to paclitaxel may result in complete resistance in vivo. Clinical studies are warranted to confirm the clinical significance of these preclinical findings in particular in patients with tumors expressing MRP but not Pgpl70.
